Senti BiosciencesSNTI
SNTI
About: Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Employees: 48
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
515% more capital invested
Capital invested by funds: $3.23M [Q4 2024] → $19.9M (+$16.6M) [Q1 2025]
2.7% more ownership
Funds ownership: 20.06% [Q4 2024] → 22.77% (+2.7%) [Q1 2025]
0% more funds holding
Funds holding: 16 [Q4 2024] → 16 (+0) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
127%
upside
Avg. target
$8.50
286%
upside
High target
$12
445%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Geulah Livshits | 445%upside $12 | Buy Maintained | 12 Jun 2025 |
Laidlaw & Co. Yale Jen | 127%upside $5 | Buy Initiated | 6 Jun 2025 |
Financial journalist opinion
Based on 9 articles about SNTI published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Senti Bio Participates in Nasdaq Amplify Spotlight Series
Access the segment here
Neutral
GlobeNewsWire
1 week ago
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference being held June 23-26, 2025 in Houston, TX.
Neutral
GlobeNewsWire
2 weeks ago
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.
Neutral
GlobeNewsWire
3 weeks ago
Senti Biosciences Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on June 3, 2025 Senti Bio's Board of Directors granted to eight new employees stock options to purchase an aggregate of 102,500 shares of the Company's common stock with a per share exercise price of $3.03. These awards were made under the Company's Amended and Restated 2022 Inducement Equity Plan (the “Plan”).
Neutral
PRNewsWire
3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or the "Company") (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
GlobeNewsWire
3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Neutral
GlobeNewsWire
3 weeks ago
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC
Moderated webcast fireside chat with members of Senti management and Chardan senior research analyst, Geulah Livshits, PhD on Monday, June 9th at 3:00 PM ET Moderated webcast fireside chat with members of Senti management and Chardan senior research analyst, Geulah Livshits, PhD on Monday, June 9th at 3:00 PM ET
Neutral
Accesswire
4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™